ACR Updates RA Advice on DMARDS, Biologics, Switching Drugs Medscape Dr. Singh pointed to 4 major changes from the 2008 ACR recommendations: The 2012 recommendations cover 3 additional biologics (certolizumab, tocilizumab, and golimumab) in addition to adalimumab, etanercept, infliximab, abatacept, and rituximab. |
